Are the Long Aβ Peptides the Real Bad Guys?
Among 14 familial Alzheimer’s APP mutations, two don’t change the Aβ42/Aβ40 ratio, but all of them yield long peptides of 45 to 49 residues that hide out in the membrane.
ALL NEWS
5781 RESULTS
Sort By:
- Most Recent
- Most Commented
Doubling Down on Sequencing Serves up More Alzheimer’s Genes
New genetic variants emerged by harmonizing whole-exome-sequencing data across continents, and by using imputation to plumb the depths of existing GWAS. One variant encodes a microglial phospholipid transporter.
ALZgerm Challenge–No Winner, But Small Prizes to 8 Scientists
Researchers split $200,000 for their theories on the role of six microbes—one virus, four bacteria, and one parasite—in Alzheimer’s.
Ready or Not: Stem Cell Therapies Poised to Enter Trials for Alzheimer’s
At Duke University, researchers discussed how injected stem cells might be tracked and used to treat neurodegenerative diseases.
New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better
At AAT-ADPD, researchers report how they built on prior reports that a person’s blood level of p-tau181 tells if they have Alzheimer’s.
Coming to a City Near You: Tracer to Picture Brain Amyloid
Amyvid, the first FDA-approved Aβ imaging ligand, is now available to researchers within reach of 16 manufacturing sites across the United States...
Moving Target: Can Standardized Tests Track Symptoms of FTD?
People with FTD wrestle with behavioral, cognitive, language, and motor impairments. Scientists are designing standardized tests that capture such symptoms.
Imaging Exposes Hugely Heterogeneous Brain Changes Among FTDs
International cohort studies reveal that the brain starts to shrink, and neural connections to crumble, many years before FTD symptoms arise. Where and when those changes occur depends on the offending mutation.
From Specialized to Standardized: Social-Emotional Tests for FTD
Disturbed social and emotional cognition are among the most troubling features of FTD. They, too, can be quantified with new tools.
Aiming at the Tangle’s Heart? DIAN-TU Trial to Torpedo Tau’s Core
The global platform trial for Alzheimer’s due to mutations in APP or presenilin will try to treat or prevent symptoms by deploying a therapeutic antibody that homes in on a piece of tau known to aggregate into neurofibrillary tangles.
Cohorts Band Together to Get Global FTD Trials Going
The FTD Prevention Initiative merges cohort studies from across the world with a common goal—to execute effective clinical trials for FTD.
Merged Consortia Forge Path to Trials in Frontotemporal Dementia
Grappling with a rare disease whose variability is daunting, international cohort studies are charting the natural history of FTD. They have discovered biomarkers and honed physiological tests that underlie its behavioral symptoms.
α-Synuclein Antibody Misses Primary, May Have Signal on Secondaries
The first topline Phase 2 results from an antibody targeting Parkinson’s pathology, Roche’s prasinezumab, were a mixed bag. Next steps are unclear.
International Conference on Frontotemporal Dementias 2021
Merged Consortia Forge Path to Trials in Frontotemporal Dementia FTD Fluid Markers for Degeneration: Check. For Pathology: Not Yet. Imaging Exposes Hugely Heterogeneous Brain Changes Among FTDs Moving Target: Can Standardized Tests Track Symptoms of FTD? ...
FTD Trials: The Now and the Future
At this year’s ICFTD meeting, researchers reviewed the lay of the land of current and planned trials for FTD, with glimpses of how the newly formed FTD Prevention Initiative seeks to coordinate treatment and prevention trials in the future.
Current Filters
- Date Range : All x